Synthace Stock
Life Sciences R&D cloud platform
Sign up today and learn more about Synthace Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthace Stock
Synthace is a R&D cloud platform. Synthace aims to automate experimentation and insight sharing for scientists to share, view, and access progress with cures and therapeutics in one place.
Synthace was founded in 2011 and is headquartered in London, White City. Notable investors include Horizons Ventures, Sofinnova Partners, Amadeus Capital Partners, and Luminous Ventures.
Funding History
August 2013 | $1.5M |
---|---|
January 2015 | $2.9M |
September 2017 | $10.5M |
June 2018 | $3.1M |
December 2018 | $25.4M |
November 2021 | $6.8M |
November 2021 | $26.8M |
Management
CEO
Guy Levy-Yurista
Co-founder & Chief Scientific Officer
Markus Gershater
Chief Product Officer
Mathieu Ayel
Press
mobihealthnews - Apr, 10 2024
Flamingo Therapeutics appoints new board member and more digital health hiresprnewswire - Mar, 20 2024
Synthace Announces Appointment of Willem Baralt as New Chairmanbusinesswire - May, 24 2023
Synthace combines ChatGPT and digital experiments in first step toward a true AI scientistbusinesswire - Apr, 5 2023
Synthace, a Digital Experiment Platform for Life Science R&D, Records Strongest Year Yetpharmiweb - Sep, 7 2022
Synthace Appoints Dr. Donald Deieso as New Board Chair